[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Pierre Fabre Dermo Cosmetique\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640966","comparison-between-different-interdental-brushes-in-adults-with-periodontal-disease-100640966",false,"NCT07575997","Comparison Between Different Interdental Brushes in Adults With Periodontal Disease.","A Clinical Study Evaluating the Efficacy of an Interdental Brush Versus Comparators in Adults With Periodontal Disease.","Inclusion Criteria:\n\n* Subject aged between 18 and 80 years included\n* Subject having signed his\u002Fher written informed consent for his\u002Fher participation in the study\n* Subject diagnosed with active generalized periodontal disease (excluding gingivitis)\n* Subject having at least 20 natural teeth (10 teeth on each side (right and left))\n\nNon-inclusion criteria:\n\n* Subject unable to understand the information given including study procedures (for linguistic or psychiatric reasons) and to give his\u002Fher consent in writing and to report required information in a questionnaire\n* For woman of childbearing potential: pregnant or breastfeeding or planning to be pregnant during the study\n* Subject having any other oral condition than periodontal disease (ex: dermatologic ulcers), or any orthodontic conditions liable to interfere with the study assessment or considered by the investigator hazardous for the subject or incompatible with study requirements\n* Systemic treatment or topical treatment\u002Fproduct currently taken\u002Fapplied in the mouth liable to interfere with study assessments according to the investigator or planned to be taken\u002Fapplied during the study\n* Subject has received periodontal therapy (scaling, root planing, surgery, etc.) within 2 months before the inclusion\n* Subject who has undergone oral or gum surgery within 2 months before the inclusion, or planned to be performed during the study","ALL","18 Years","80 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this exploratory study is to evaluate the efficacy of the tested interdental brush versus comparative interdental brushes in adults with periodontal disease, over a 4-week period.",[27],"Periodontal Disease",[27,29],"Interdental Brushes","RECRUITING","2026-05-04",{"date":33,"type":34},"2026-05-08","ACTUAL",{"date":36,"type":34},"2026-04-10",{"date":38,"type":21},"2027-06-30",{"name":40,"class":41},"Pierre Fabre Dermo Cosmetique","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":42},"100594020","tolerance-and-efficacy-open-label-study-with-rv4421b-in-various-populations-with-atopic-dermatitis-for-12-weeks-100594020","NCT07014007","Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks","Open-label Study to Assess the Tolerance and Efficacy of the Product RV4421B-EV0407, Applied in Paediatric and Adult Populations With Mild to Moderate Atopic Dermatitis for 12 Weeks","Inclusion criteria:\n\n* Male or female, with any phototype according to Fitzpatrick classification aged:\n* Group 1 (infants group): from 3 months to 23 months old included\n* Group 2 (children group): from 24 months to 12 years old included\n* Group 3 (teenagers \\& adults group): from 13 years old\n* Subject with a diagnosis of atopic dermatitis according to the U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis (Williams HC, Burney PG, et al.).\n* Subject with studied areas (lesions and prevailing xerotic areas) limited up to 30% of the body surface area\n* Subject with mild to moderate Atopic Dermatitis\n\nCriteria related to treatments and\u002For products:\n\n• Topical corticosteroids treatments (following international treatment guidelines for each age sub-group and including investigator agreement) applied on AD lesions areas since 1 to 5 days before the inclusion and ongoing at the time of inclusion. \\*\n\n\\*The investigator will be authorized to adjust the treatment during the study.\n\nExclusion criteria:\n\nCriteria related to the skin condition or the disease:\n\n* Infant with Atopic Dermatitis lesions or prevailing xerotic areas located on the diaper (groups 1 \\& 2)\n* Subject with history of allergy or intolerance to any of the study product(s) ingredients or material used for the research\n* Subject having any other dermatologic condition than Atopic Dermatitis, or characteristics (like tattoo…) on the studied areas liable to interfere with the study assessments\n* Subject having a dermatological condition, an acute, chronic or progressive disease or history of disease liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements\n* Knowledge of Acquired Immunodeficiency Syndrome or Infectious (acute or chronic)\n\nCriteria related to treatments and\u002For products:\n\n* Systemic biological immunosuppressive treatment established or modified within 12 weeks before the inclusion or planned to be started during the study\n* Phototherapy performed within 4 weeks before the inclusion visit or planned to be started during the study\n* Systemic non-biological immunosuppressive treatment established or modified within 4 weeks before the inclusion or ongoing or planned to be started during the study\n* Systemic corticosteroids treatment established or modified within 4 weeks before the inclusion or ongoing or planned to be started during the study\n* Systemic antibiotics for dermatological purposes treatment established or modified within 2 weeks before the inclusion or ongoing or planned to be started during the study\n* Systemic antihistaminic treatment established or modified within 2 weeks before the inclusion\n* Topical treatments (immunomodulators (TIMs), non-steroidal anti-inflammatory, antihistaminic, antibiotics for dermatological purposes or antiseptics) applied on studied areas within 1 week before the inclusion or ongoing or planned to be started during the study\n* Any other topical treatment or product applied on studied areas incompatible with the study or liable to interfere with the study assessments according to the investigator, in the weeks prior to the inclusion visit, ongoing or planned to be started during the study\n* Skin care product (including moisturizer) applied on the whole body between the evening before the visit and the inclusion.\n* Water and\u002For any cleansing product, applied on the whole body within 4 hours before the inclusion visit. If there is no studied area on the face, the subject is allowed to do a light face wash without time restriction (especially in the morning of the visit).\n* Subject who plans to modify his\u002Fher usual moisturizer (allowed outside studied areas) and\u002For care habits during the study\n\nTreatment of the mother if the subject of group 1 and 2 is breastfed:\n\n* Systemic biological immunosuppressive treatment established or modified within 12 weeks before the inclusion or planned to be started during the study\n* Systemic non-biological immunosuppressive treatment established or modified within 4 weeks before the inclusion or planned to be started during the study\n* Systemic corticosteroids established or modified within 2 weeks before the inclusion or planned to be started during the study\n* Systemic antihistaminic established or modified within 2 weeks before the inclusion\n* Systemic antibiotics for dermatological purposes established or modified within 1 week before the inclusion or planned to be started during the study","3 Months",{"count":52,"type":21},105,[24],"Pierre Fabre Laboratories have developed a cream with medical device status, RV4421B-EV0407 indicated for the treatment of eczemas, including atopic eczema, contact eczema and chronic hand eczema.\n\nThis product is already marketed in several countries. The objective of this clinical study is to evaluate the safety and efficacy of the study product when used alone or in association with topical corticosteroid therapy, in an ethnically diverse adult and pediatric population (including dark skin) and over a long period of time with a 12-week follow-up.\n\n5 visits are planned:\n\n* Visit 1: Inclusion visit (Day 1)\n* Visit 2: Intermediate visit (Phone visit - Between Day 8 and Day 15)\n* Visit 3: Intermediate visit (Day 29 ± 3 days)\n* Visit 4: Intermediate visit (Day 57 ± 3 days)\n* Visit 5: End of study visit (Day 85 ± 3 days)",[56],"Atopic Dermatitis",[56,58,59,60,61,62,63,64,65,66],"Eczema","Flare","Inflammatory skin disease","Altered skin barrier","Dryness","Itching","Redness","Stinging","Burning sensation",{"date":68,"type":34},"2026-05-05",{"date":70,"type":34},"2025-09-30",{"date":72,"type":21},"2026-11",{"name":40,"class":41},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":42},"100571142","a-comparative-study-of-cosmetic-product-in-subjects-with-facial-acne-during-an-associated-treatment-phase-followed-by-a-maintenance-phase-100571142","NCT06716398","A Comparative Study of Cosmetic Product in Subjects With Facial Acne During an Associated-treatment Phase Followed by a Maintenance Phase","A Randomized Investigator-blinded Comparative Study to Assess the Efficacy of the Cosmetic Care Product RV4133C - Formula JT2559 in Subjects With Facial Acne, During a 3-month-associated-treatment Phase Followed by a 3-month-maintenance Phase","Inclusion Criteria:\n\n* Male or Female aged between 14 and 24 years (included)\n* Subject with facial acne with score index severity IGA = 2 or 3, assessed on a scale ranged from 0 to 4.\n* Subject for whom a prescription of 12 weeks of a reference topical medical treatment is required from the day of the inclusion visit, for mild to moderate face acne\n\nExclusion Criteria:\n\nCriteria related to the disease:\n\n* Facial skin disease other than acne, skin abnormalities, or dermatological condition on the face liable to interfere with the study assessments\n* Acne conglobata, Acne fulminans, nodulocystic acne or acneiform eruptions, according to investigator's assessment\n* Other type of pigmentation disorder than acne-related PIH liable to interfere with the study assessments according to the investigator\n\nCriteria related to treatments and\u002For products:\n\n\\- Topical or oral treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational products","14 Years","24 Years",{"count":84,"type":21},60,[24],"In this study, we are interested in the global benefit of the tested product as complementary care to a topical medical treatment during a 3 month-associated treatment phase followed by a 3 month-maintenance phase, compared to a light moisturizing cream, in teenagers and adults with acne. We also want to evaluate the tolerance of the tested product in association and in maintenance of the topical medical treatment.",[88],"Acne",[90,91,92,93,94,95],"acne","face","young adults","teenagers","treatment phase","maintenance","2024-11-29",{"date":98,"type":34},"2024-12-04",{"date":100,"type":34},"2024-07-03",{"date":102,"type":21},"2025-07-30",{"name":40,"class":41},""]